English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Human leukocyte antigen (HLA) alleles are implicated in drug-induced hypersensitivity, including by nevirapine and abacavir. The purpose of this meta-analysis was to evaluate the relationship between HLA polymorphisms and hypersensitivity to antiretroviral therapy in human immunodeficiency virus (HIV)-infected patients.    Methods  We conducted a systematic search of PubMed, Embase, Web of Science, and the Cochrane Library for studies that evaluated the associations of HLA polymorphisms with antiretroviral therapy-induced hypersensitivity published in April 2019. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were considered as estimates of the effect.    Results  The meta-analysis included 17 studies that assessed a total of 4273 patients. First, carriers of HLA-A *24 were associated with an increased risk of hypersensitivity among patients with HIV who received antiretroviral therapy (OR: 12.12;  P  = 0.018). Second, five SNPs of HLA-B genotypes, including *18 (OR: 1.63;  P  = 0.028), *35 (OR: 2.31;  P  = 0.002), *39 (OR: 11.85;  P  = 0.040), *51 (OR: 1.66;  P  = 0.028), and *81 (OR: 8.11;  P  = 0.021), were associated with an increased risk of hypersensitivity. Conversely, carriers of HLA-B *15 were associated with a reduced risk of hypersensitivity (OR: 0.43;  P  < 0.001). Third, HLA-C *04 was associated with an increased risk of hypersensitivity (OR: 3.09;  P  < 0.001), whereas a lower risk for hypersensitivity was observed in patients who were carriers of HLA-C *02 (OR: 0.22;  P  = 0.030), *03 (OR: 0.53;  P  = 0.049), and *07 (OR: 0.61;  P  = 0.044). Finally, carriers of HLA-DRB1 *05 (OR: 0.18;  P  = 0.006) and *15 (OR: 0.23;  P  = 0.013) were associated with a reduced risk of hypersensitivity among patients receiving antiretroviral therapy.    Conclusions  The findings of this meta-analysis indicated patients carrying HLA-A *24, HLA-B *18, *35, *39, *51, *81, HLA-C *04 were associated with a higher risk of hypersensitivity. Conversely, subjects carrying HLA-B *15, HLA-C *02, *03, *07, HLA-DRB1 *05, *15 were associated with a reduced risk of hypersensitivity.    Electronic supplementary material  The online version of this article (10.1186/s12879-019-4227-5) contains supplementary material, which is available to authorized users.

bmc infectious diseases

Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis